MedTrace Logo

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

NCT02950766 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-02-03

No results posted yet for this study

Summary

This research study is evaluating a new type of Kidney Cancer vaccine called "Personalized NeoAntigen Cancer Vaccine"as a possible treatment for Kidney Cancer.

The following intervention will be involved in this study:

* Personalized Neoantigen Vaccine
* Poly-ICLC (Hiltonol)
* Ipilimumab

Conditions

Interventions

DRUG

NeoVax

combination of Neoantigen peptides and poly-ICLC

DRUG

Ipilimumab

local administration of ipilimumab

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • Oncovir, Inc.

    collaborator INDUSTRY

  • Patrick Ott, MD, PhD

    lead OTHER

Principal Investigators

  • Patrick Ott, MD · Dana-Farber Cancer Institute

  • Toni Choueiri, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-03
Primary Completion
2027-12-31
Completion
2030-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02950766 on ClinicalTrials.gov